SCHOTT Pharma Expands Capacity with New RTU Cartridge Facility in Hungary

SCHOTT Pharma Expands Capacity with New RTU Cartridge Facility in Hungary

(IN BRIEF) SCHOTT Pharma has begun construction on a new production facility for ready-to-use (RTU) cartridges at its Lukácsháza site in Hungary. The investment of over 100 million euros will expand the company’s manufacturing capacity to meet increasing demand for high-value solutions used in drug containment and delivery. The facility will add more than 100 new jobs and will support the production of sterile cartridges used in biologics, GLP-1 drugs, and insulin therapies. This expansion follows the opening of a prefillable glass syringe facility at the same site in 2024 and is part of SCHOTT Pharma’s broader strategy to enhance its market position in the diabetes and obesity fields.

(PRESS RELEASE) LUKÃCSHAZA, 5-Jun-2025 — /EuropaWire/ — SCHOTT Pharma has officially broken ground on a new production facility for ready-to-use (RTU) cartridges at its Lukácsháza site in Hungary, marking a significant investment of over 100 million euros. This expansion is a key component of the company’s strategy to address the growing market demand for high-value solutions in the pharmaceutical industry. The new facility will boost the production capacity for RTU cartridges, which are essential for storing biologics, GLP-1 drugs, insulin, and hormone therapies used in treating diabetes, obesity, and other immunological conditions. The project will create over 100 new jobs in the region.

Symbolic start of construction: L to R Dr. István Orbán, Director General of Vas County Government Office, Dominique Bauert, Head of Strategic Business Field Sterile Solutions at SCHOTT Pharma, Péter Ágh, Hungarian State Secretary for Construction and Transport, Eva Szabó, Site Manager Lukácsháza, Dr. Torsten Derr, CEO SCHOTT AG, Andreas Reisse, CEO SCHOTT Pharma, István Joó, Government Commissioner and CEO Hungarian Investment Promotion Agency (HIPA), Fabian Stöcker, Head of Business Segment Drug Containment Solutions at SCHOTT Pharma, and János Virág, Mayor of Lukácsháza bury time capsule at groundbreaking event. Photo: SCHOTT Pharma/Péter Benkő

In addition to this new facility, SCHOTT Pharma had already opened a state-of-the-art facility for prefillable glass syringes at the same site in 2024. The company’s expansion plans align with its broader growth strategy, aimed at increasing its market share in high-margin, sterile drug containment solutions. “As we work to meet the rising demand, particularly in the diabetes and obesity sectors, this investment in Hungary underscores our commitment to expanding our manufacturing capabilities,” said Andreas Reisse, CEO of SCHOTT Pharma.

The new facility will feature advanced machinery, an innovative washing line, and a steam sterilization process for cartridges to minimize environmental impact. Manufacturing will be highly automated with minimal manual intervention, ensuring the highest standards of quality for sterile products. Following its St. Gallen, Switzerland location, Lukácsháza will become the second SCHOTT Pharma site dedicated to manufacturing sterile RTU cartridges.

Eva Szabó, Site Manager of Lukácsháza, expressed gratitude for the support from the Ministry of Foreign Affairs and Trade and emphasized the strategic importance of the site for both local and global supply chains. The new facility will support SCHOTT Pharma’s global growth, further enhancing its role in the pharmaceutical industry.

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 25,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com

Media Contact:

Lea Kaiser
PR & Communications Manager
+49 (0) 6131 66-2422

SOURCE: SCHOTT Pharma